True Wearables, Inc., a medical device start-up based in Orange County, CA, announced today Oxxiom, the world's first wireless, continuous, fully disposable, single-use pulse oximeter.
Pulse oximetry is a noninvasive method for monitoring a person's oxygen saturation (SO2). A blood-oxygen monitor displays the percentage of blood that is loaded with oxygen by measuring what percentage of hemoglobin, the protein in blood that carries oxygen, is loaded. Acceptable normal ranges for patients without pulmonary pathology are from 95 to 99 percent. In its most common applications a sensor device is placed on a thin part of the patient's body, usually a fingertip or earlobe, or in the case of an infant, across a foot.
Oxxiom measures arterial oxygen saturation (SpO2), pulse rate (PR), and perfusion index (PI).
True Wearables' innovative design has combined the electronics and biosensing technology of a clinical grade pulse oximeter into a tiny, easy-to-use, and completely wireless device that offers over 24 hours of continuous monitoring.
Oxxiom weighs only 0.12 ounces (3.5 grams) and is completely disposable, eliminating the need for sterilization and significantly reducing the risks of cross contamination.
Oxxiom's proprietary technology offers total mobility in a 33 feet range and allows users to sleep in any position, exercise, use the restroom, wash their hands, or take a shower while connected to the device. Oxxiom is monitor agnostic, and works with mobile devices, tablets, laptops and desktops. Oxxiom does not require external batteries or battery chargers and its operation is not affected by nail polish or ambient light.
Pulse oximetry is a technology that enables the non-invasive monitoring of a patient's arterial oxygen saturation (SpO2), pulse rate (PR), and perfusion index (PI) and gives doctors an indication of the patient's cardiorespiratory status. Pulse oximeters are widely utilized on procedures that require anesthesia or sedation, and during sleep monitoring studies. They are also used to monitor conditions that affect oxygen blood levels, such as heart attack, heart failure, anemia, COPD, and apnea. Oxxiom is expected to ship in Q2 2016.
Specifications are subject to change without notice.
True Wearables is a medical device company founded in 2014 by Marcelo Lamego, Ph.D. Stanford University, previously of The Boston Consulting Group, Masimo, Cercacor and Apple. Additional information about their company and products can be found at truewearables.com